Literature DB >> 14578473

New tools for cancer chemotherapy: computational assistance for tailoring treatments.

Shea N Gardner1, Michael Fernandes.   

Abstract

Computational models of cancer chemotherapy have the potential to streamline clinical trial design, contribute to the design of rational, tailored treatments, and facilitate our understanding of experimental results. Mechanistic models based on functional data from tumor biopsies will enable physicians to predict response to treatment for a specific patient, in contrast to statistical models in which the probability of response for a given patient may differ substantially from the population average. While microarray analyses of gene expression also show promise for guiding individualized treatments, it may be difficult to link statistical mining of microarray data with mechanistic, tailored treatments. Furthermore, gene expression does not identify how drugs should be scheduled. This review summarizes mechanistic mathematical models developed to improve the design of chemotherapy regimens. Mechanistic models that incorporate both genetic resistance and cell cycle-mediated resistance during treatment with multiple drugs will be most useful in designing treatment regimens tailored for individuals. Because there are already a number of papers that address the applications of microarray technology, we will limit our discussion to the contrasts between mechanistic computational models and microarray technology, and how these two approaches may complement one another.

Entities:  

Mesh:

Year:  2003        PMID: 14578473

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  7 in total

Review 1.  The dynamics of drug resistance: a mathematical perspective.

Authors:  Orit Lavi; Michael M Gottesman; Doron Levy
Journal:  Drug Resist Updat       Date:  2012-03-03       Impact factor: 18.500

2.  A preclinical assay for chemosensitivity in multiple myeloma.

Authors:  Zayar P Khin; Maria L C Ribeiro; Timothy Jacobson; Lori Hazlehurst; Lia Perez; Rachid Baz; Kenneth Shain; Ariosto S Silva
Journal:  Cancer Res       Date:  2013-12-05       Impact factor: 12.701

3.  Optimizing combination therapies with existing and future CML drugs.

Authors:  Allen A Katouli; Natalia L Komarova
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

4.  Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.

Authors:  Jasmine Foo; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2009-11-06       Impact factor: 4.475

Review 5.  In silico modelling of treatment-induced tumour cell kill: developments and advances.

Authors:  Loredana G Marcu; Wendy M Harriss-Phillips
Journal:  Comput Math Methods Med       Date:  2012-07-12       Impact factor: 2.238

6.  Cell killing and resistance in pre-operative breast cancer chemotherapy.

Authors:  Paolo Ubezio; David Cameron
Journal:  BMC Cancer       Date:  2008-07-21       Impact factor: 4.430

7.  Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.

Authors:  Lin L Liu; Fei Li; William Pao; Franziska Michor
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.